(VIANEWS) – Lantheus Holdings (LNTH), Inter Parfums (IPAR), Rayonier REIT (RYN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Lantheus Holdings (LNTH)
16.4% sales growth and 51.73% return on equity
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.
Earnings Per Share
As for profitability, Lantheus Holdings has a trailing twelve months EPS of $4.65.
PE Ratio
Lantheus Holdings has a trailing twelve months price to earnings ratio of 13.09. Meaning, the purchaser of the share is investing $13.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 51.73%.
Moving Average
Lantheus Holdings’s worth is above its 50-day moving average of $58.83 and way under its 200-day moving average of $69.81.
Previous days news about Lantheus Holdings(LNTH)
- Why lantheus holdings (lnth) outpaced the stock market today. According to Zacks on Wednesday, 20 March, "The upcoming earnings release of Lantheus Holdings will be of great interest to investors. ", "From a valuation perspective, Lantheus Holdings is currently exchanging hands at a Forward P/E ratio of 8.89. "
2. Inter Parfums (IPAR)
11.7% sales growth and 22.35% return on equity
Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products in the United States and internationally. It operates in two segments, European Based Operations and United States Based Operations. The company offers its fragrance and cosmetic products under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lanvin, Moncler, Montblanc, Rochas, S.T. Dupont, Van Cleef & Arpels, Abercrombie & Fitch, Anna Sui, Donna Karan, DKNY, Ferragamo, Graff, GUESS, Hollister, MCM, Oscar de la Renta, and Ungaro brands, as well as French Connection, Intimate, and Aziza names. It sells its products to department stores, specialty stores, duty free shops, beauty retailers, and domestic and international wholesalers, and distributors, as well as through e-commerce. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1982 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Inter Parfums has a trailing twelve months EPS of $4.75.
PE Ratio
Inter Parfums has a trailing twelve months price to earnings ratio of 29.49. Meaning, the purchaser of the share is investing $29.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.35%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 4.2% and 5.5%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Inter Parfums’s EBITDA is 3.38.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.8%, now sitting on 1.32B for the twelve trailing months.
3. Rayonier REIT (RYN)
8.6% sales growth and 9.05% return on equity
Rayonier is a leading timberland real estate investment trust with assets located in some of the most productive softwood timber growing regions in the United States and New Zealand. As of December 31, 2020, Rayonier owned or leased under long-term agreements approximately 2.7 million acres of timberlands located in the U.S. South (1.73 million acres), U.S. Pacific Northwest (507,000 acres) and New Zealand (417,000 acres). The Company also acts as the managing member in a private equity timber fund business with three funds comprising approximately 141,000 acres. On a “look-through basis”, the Company's ownership in the timber fund business equates to approximately 17,000 acres.
Earnings Per Share
As for profitability, Rayonier REIT has a trailing twelve months EPS of $1.17.
PE Ratio
Rayonier REIT has a trailing twelve months price to earnings ratio of 28.11. Meaning, the purchaser of the share is investing $28.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.05%.
4. Diamondback Energy (FANG)
8.1% sales growth and 20.15% return on equity
Diamondback Energy, Inc., an independent oil and natural gas company, acquires, develops, explores, and exploits unconventional, onshore oil and natural gas reserves in the Permian Basin in West Texas. It focuses on the development of the Spraberry and Wolfcamp formations of the Midland basin; and the Wolfcamp and Bone Spring formations of the Delaware basin, which are part of the Permian Basin in West Texas and New Mexico. The company also owns and operates midstream infrastructure assets, in the Midland and Delaware Basins of the Permian Basin. Diamondback Energy, Inc. was founded in 2007 and is headquartered in Midland, Texas.
Earnings Per Share
As for profitability, Diamondback Energy has a trailing twelve months EPS of $17.34.
PE Ratio
Diamondback Energy has a trailing twelve months price to earnings ratio of 11.12. Meaning, the purchaser of the share is investing $11.12 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.15%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Diamondback Energy’s EBITDA is 4.67.
Yearly Top and Bottom Value
Diamondback Energy’s stock is valued at $192.90 at 06:22 EST, higher than its 52-week high of $185.78.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.3%, now sitting on 7.96B for the twelve trailing months.
Previous days news about Diamondback Energy(FANG)
- According to Zacks on Wednesday, 20 March, "Last month, the energy market witnessed a $26 billion deal between Diamondback Energy and Endeavor Energy Resources LP to create a leading oil and natural player in the Permian - the most prolific basin in the United States."
5. American Electric Power Company (AEP)
7.6% sales growth and 8.96% return on equity
American Electric Power Company, Inc., an electric public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers in the United States. It operates through Vertically Integrated Utilities, Transmission and Distribution Utilities, AEP Transmission Holdco, and Generation & Marketing segments. The company generates electricity using coal and lignite, natural gas, renewable, nuclear, hydro, solar, wind, and other energy sources. It also supplies and markets electric power at wholesale to other electric utility companies, rural electric cooperatives, municipalities, and other market participants. American Electric Power Company, Inc. was incorporated in 1906 and is headquartered in Columbus, Ohio.
Earnings Per Share
As for profitability, American Electric Power Company has a trailing twelve months EPS of $4.24.
PE Ratio
American Electric Power Company has a trailing twelve months price to earnings ratio of 19.54. Meaning, the purchaser of the share is investing $19.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.96%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 24.3% and 8%, respectively.
Sales Growth
American Electric Power Company’s sales growth is 4.9% for the ongoing quarter and 7.6% for the next.
6. GlaxoSmithKline (GSK)
6.3% sales growth and 46.38% return on equity
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Earnings Per Share
As for profitability, GlaxoSmithKline has a trailing twelve months EPS of $3.05.
PE Ratio
GlaxoSmithKline has a trailing twelve months price to earnings ratio of 13.75. Meaning, the purchaser of the share is investing $13.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 46.38%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 22, 2024, the estimated forward annual dividend rate is 1.47 and the estimated forward annual dividend yield is 3.4%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 30.33B for the twelve trailing months.
